Astrana Health, Inc. (ASTH) Stock Price & Analysis
Astrana Health, Inc. (ASTH) closed at USD 38.01 on Thursday, October 22, 2026, up 1.77% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 38.01; the Oct 22, 2026 session ranged USD 37.21–38.47 on volume of 213,886 shares. Market capitalization is —, with a 52-week range of USD 18.08–51.6 (NCM). Source: Nexqual, retrieved October 23, 2026 at 10:37 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ASTH.md
Key facts (ASTH)
- Last four reported quarters (through Jun 30, 2026): revenue $3.84B, net income $40.5M (1.1% margin), free cash flow $94.4M (SEC filings).
- Total return with dividends: 1Y +14.6% vs S&P 500 +14.9%; 5Y -47.2% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD 0.88, revenue estimate $1.02B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ASTH)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $774M | $1.14B | $1.39B | $2.03B | $3.18B | $3.84B |
| Gross profit | $178M | — | — | — | — | — |
| Operating income | $98.2M | $104M | $84.6M | $89.3M | $78.5M | $100M |
| Net income | $68.9M | $45.2M | $60.7M | $43.1M | $22.5M | $40.5M |
| EPS (diluted) | $1.52 | $0.99 | $1.29 | $0.90 | $0.46 | — |
| Free cash flow | $51.1M | $59.2M | $39.7M | $44.2M | $104M | $94.4M |
| Gross margin | 23.0% | — | — | — | — | — |
| Operating margin | 12.7% | 9.1% | 6.1% | 4.4% | 2.5% | 2.6% |
| Net margin | 8.9% | 3.9% | 4.4% | 2.1% | 0.7% | 1.1% |
| Revenue growth | +12.6% | +47.8% | +21.2% | +46.7% | +56.4% | — |
| Cash + short-term investments | $287M | $294M | $296M | $291M | — | — |
| Total debt | $184M | $204M | $278M | $435M | $1.04B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ASTH)
P/E at fiscal year-ends: Dec 2025 54.5x, Dec 2024 35.1x, Dec 2023 29.6x.
Analysts (ASTH)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | Freedom Capital Markets | Maintained | Buy | $50 |
| 2026-09-15 | Oppenheimer | Initiated | Outperform | $53 |
| 2026-08-11 | Truist Securities | Target raised | Buy | $47 → $55 |
| 2026-08-07 | Barclays | Target raised | Overweight | $50 → $53 |
| 2026-07-14 | TD Cowen | Target raised | Buy | $45 → $50 |
| 2026-07-14 | BTIG | Target raised | Buy | $50 → $65 |
Total return (dividends reinvested) (ASTH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +14.6% | -47.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +14.7% | -12.0% |
| Volatility (annualized) | 68.0% | 58.8% |
| Max drawdown | -46.4% (Oct 2025→Feb 2026) | -83.5% (Nov 2021→Feb 2026) |
ASTH revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Care Partners | $932.8M | 95.9% | +47.7% |
| Care Enablement | $85.6M | 8.8% | +109.3% |
| Care Delivery | $74.7M | 7.7% | +94.6% |
| Total revenue | $972.5M | 100% | — |
ASTH revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Health Care Capitation Revenue | $905.8M | 93.1% | +47.5% |
| Health Care Patient Service | $23.0M | 2.4% | +28.5% |
| Health Care Other | $21.8M | 2.2% | +41.6% |
| Management Service | $13.2M | 1.4% | +412.7% |
| Product & Service Other | $8.7M | 0.9% | +79.8% |
| Total revenue | $972.5M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ASTH suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Prospect Medical Holdings | “In such event, we would have limited to no recourse against the Prospect PhysicianCo Entities due to their bankruptcy filing, the elimination of the escrow account to cover, among other things, non-assumed liabilities of the Prospect PhysicianCo Entities, and the elimination of recourse (with certain exceptions) against the Prospect PhysicianCo Entities, as set forth in our letter agreement with Prospect dated Jul…” |
| Competitor | UnitedHealth (UNH) | “In the greater Los Angeles area, such competitors include Regal Medical Group and Lakeside Medical Group, which are part of Heritage Provider Network ("Heritage"), as well as Optum, a subsidiary of UnitedHealth Group.” |
Quoted from the company's 10-K filed Mar 12, 2026.
ASTH customer concentration
In the period ended Jun 30, 2026, 4 direct customers each accounted for at least 10% (18.5%, 15.3%, 10.3%, 10.1%) of revenue, per the company's 10-Q filed Aug 10, 2026. The company does not name them.
ASTH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.88 | $0.79 | +11.0% | $1.02B | 3 |
| Next quarter (ends Dec 2026) | $0.65 | $0.66 | -0.8% | $1.02B | 3 |
| Current fiscal year (ends Dec 2026) | $3.07 | $2.92 | +5.0% | $3.98B | 3 |
| Next fiscal year (ends Dec 2027) | $3.64 | $3.41 | +6.6% | $4.38B | 3 |
ASTH options: expected move
Options price a move of about ±18.5% (±$7.03) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±15.1% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 78.3% | ±18.5% |
| Dec 18, 2026 | 56 | 67.2% | ±22.0% |
| Feb 19, 2027 | 119 | 61.6% | ±28.8% |
| May 21, 2027 | 210 | 62.0% | ±37.9% |
30-day implied volatility 67.9% vs 50.8% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 10:37 UTC)
| Price | USD 38.01 |
|---|---|
| Change | ▲ 1.77% (up) |
| Previous Close | USD 38.01 |
| Open | USD 38.01 |
| Day Range | USD 37.21 – 38.47 |
| 52-Week Range | USD 18.08 – 51.6 |
| Volume | 213,886 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ASTH)
Nexqual's technical model rates ASTH "STRONG BUY" based on 5 bullish and 0 bearish signals across 127 daily candles, as of October 23, 2026 at 10:37 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 52.5 (neutral) |
| vs SMA50 | Above (USD 37.37) |
| MACD | 0.27 (positive) |
Earnings (ASTH)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 0.88 |
| Revenue Estimate | $1.02B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.8 vs est 0.73 ▲ beat |
| 2026-03-31 | USD 0.74 vs est 0.65 ▲ beat |
| 2025-12-31 | USD 0.42 vs est 0.33 ▲ beat |
| 2025-09-30 | USD 0.67 vs est 0.61 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Financials & Fundamentals (ASTH)
| Total Revenue | $3.84B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +48.50% |
| Gross Margin | +10.46% |
| Operating Margin | +3.53% |
| Profit Margin | +1.05% |
| ROE | +6.90% |
| Debt / Equity | 1.64 |
| Current Ratio | 1.23 |
| Total Cash | $400.79M |
| Total Debt | $979.41M |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
Ownership (ASTH)
| Insider Ownership | +22.78% |
|---|---|
| Institutional Ownership | +66.71% |
| Shares Outstanding | 49.60M |
| Float | 45.67M |
| Short % of Float | +11.86% |
Source: Nexqual, October 23, 2026 at 10:37 UTC.
From Astrana Health, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)
Key Strengths & Strategy (as disclosed to the SEC)
- Leveraging its proprietary end-to-end technology solutions, Astrana operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver accessible, high-quality care to patients in a cost-effective manner.
- Our Care Delivery organization spans over 60 locations and includes: Primary care clinics, including post-acute care services and an acute care hospital facility; Specialty care clinics and inpatient services, including cardiac care, endocrinology, and ophthalmology, as well as hospitalist and intensivist services; and Ancillary service providers, such as urgent care centers, outpatient imaging centers, ambulatory surgery centers, full-service labs, and a specialty pharmacy.
- Our Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information, all powered by our proprietary technology suite.
- Through our integrated health network of more than 20,000 contracted physicians, we were responsible for coordinating value-based care for approximately 1.6 million patients as of December 31, 2025.
Partnerships
- Via a Physician Shareholder Agreement with the nominee shareholder, the Company has the ability to designate another person as the equity holder of the professional corporation.
- Pursuant to our risk-share agreement with CMS, we are eligible to receive the surplus (shared savings) or are liable for the deficit (shared losses) according to the budgetary benchmark established by CMS based on our efficiency, or lack thereof, in managing the expenditures associated with our Aligned Beneficiaries.
Legal & Regulatory Risks (Item 1A, quoted)
- The Company's complex legal structure may cause tax authorities to question our tax filing status. The Company can be adversely impacted if a tax authority does not agree with our position.
- The healthcare industry is intensely regulated at the federal, state, and local levels, and government authorities may determine that we fail to comply with applicable laws or regulations and take action against us. In addition, changes to federal, state, and local healthcare law, including the ACA and/or the adoption of a primarily publicly funded healthcare system, may negatively impact our business.
- We are also subject to laws and regulations not specifically targeting the healthcare industry, compliance with which could require significant expenditures, and failing to comply with such laws could result in sanctions and penalties.
- Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business, and the failure to comply with such laws could subject us to penalties and restructuring.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AMN | AMN Healthcare Services Inc | USD 46.82 | ▲ 8.86% |
| ARDT | Ardent Health, Inc. | USD 12.36 | ▲ 2.49% |
| SGRY | Surgery Partners, Inc. | USD 15.9 | ▲ 3.25% |
| HCSG | Healthcare Services Group, Inc. | USD 24.79 | ▲ 14.19% |
| SNDA | Sonida Senior Living, Inc. | USD 33.87 | ▲ 1.2% |
| CMPS | COMPASS Pathways Plc - American | USD 11.63 | ▼ 1.77% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:37 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt